The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.16% and ...

Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) ...

Eli Lilly ( LLY -0.44%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

We recently published a list of Jim Cramer’s Latest Calls: Top 10 Stocks. In this article, we are going to take a look at ...

Eli Lilly ( LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound.

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...

The agency is due to make a determination on the shortage status of Zepbound by Dec. 19. But another delay could be possible ...

David Ricks told a lunch audience at the Economic Club of Washington, D.C., that Zepbound could quickly become the most ...